According to documents submitted to the U.S. Securities and Exchange Commission, Centessa Pharmaceuticals plc announced that a key closing condition for its transaction with Eli Lilly has been satisfied—the expiration of the waiting period under the Hart-S
Centessa Pharmaceuticals plc announced that a key closing condition for its transaction with Eli Lilly, the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, has been satisfied. This regulatory clearance removes a major obstacle, allowing both parties to proceed towards the transaction's completion. Other customary closing conditions, including shareholder approval, still need to be met.
Next-gen obesity drug helps patients lose 28% of body weight: Eli Lilly
Eli Lilly's experimental weight-loss injection, Retatrutide, showed promising results in a phase-three trial, with patients losing an average of 28.3% of their body weight. This next-generation drug targets three metabolic processes, offering greater efficacy than existing medications like Zepbound and Wegovy. While effective, about 11% of patients on the highest dose discontinued due to side effects, including nausea and vomiting.
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement
Gilead Sciences Inc. (GILD) stock closed up by 3.04% on May 22, outperforming its sector, driven primarily by significant advancements in its product pipeline and regulatory milestones. Key drivers include the FDA approval of Hepcludex for chronic hepatitis delta virus infection and the European Medicines Agency's positive recommendation for Trodelvy in advanced breast cancer. Despite some reports of insider selling and a lowered Q4 2026 EPS estimate, these positive developments provided a strong catalyst for the stock's upward movement.
HSR waiting period lapses for Centessa (CNTA) sale to Eli Lilly under UK scheme
Centessa Pharmaceuticals announced that the Hart-Scott-Rodino (HSR) antitrust waiting period for its acquisition by Eli Lilly expired on May 21, 2026, fulfilling a key condition for the deal. However, the acquisition, structured as a court-sanctioned scheme of arrangement in the U.K., still requires approval from Centessa shareholders and sanction by the High Court of Justice of England and Wales. The company also highlighted various risks that could delay or prevent the completion of the transaction.
Eli Lilly sues church leaders for alleged $200 million 'sham' drug program
Eli Lilly has filed a lawsuit against leaders of the Church of God in Christ (COGIC), including Bishop Jerry Maynard Sr. and Elder Readus C. Smith III, alleging they defrauded the company of over $200 million in diabetes drug rebates. The pharmaceutical giant claims that a cost-sharing program for church members was a "sham" designed to resell drugs through wholesalers rather than dispense them to patients, while fraudulently collecting rebates. This lawsuit follows Eli Lilly's prior concerns and termination of agreement with DrugPlace, a primary alleged participant, in 2015 due to rebate irregularities.
Merck & Co Inc Stock (MRK) Opened Up by 4.50% on May 22: Facts Behind the Movement
Merck & Co Inc (MRK) saw its stock open up by 4.50% on May 22, driven primarily by positive Phase III clinical trial results for its sacituzumab tirumotecan (sac-TMT) in combination with Keytruda for lung cancer. Upcoming extensive oncology data presentations at the ASCO meeting and strong Q1 2026 earnings that surpassed expectations further contributed to the optimistic investor sentiment. Despite recent setbacks like a failed trial and a downgrade from one analyst, the company's financial performance and strategic pipeline developments are buoying its stock price.
Keudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRK
Keudell Morrison Wealth Management recently invested $1.33 million in Merck & Co., Inc. (NYSE:MRK), purchasing 12,657 shares in the fourth quarter. The pharmaceutical giant has shown positive operating and pipeline updates, including beating earnings estimates and promising results from oncology trials. Despite some neutral and negative sentiments from analysts, Merck maintains a "Moderate Buy" rating with an average price target of $128.18.
Report: Novo Nordisk’s Wegovy tablet continues to gain traction in the US
Novo Nordisk's Wegovy weight-loss tablet and Eli Lilly's Foundayo are both increasing their prescription numbers in the US. Wegovy reported over 109,000 prescriptions last week, although these figures do not include all sales channels like online pharmacies. Eli Lilly's new tablet, Foundayo, also saw a modest increase to 2,520 prescriptions.
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company
Eli Lilly and Company announced positive topline results from its TRIUMPH-1 Phase 3 clinical trial for retatrutide, an investigational triple hormone receptor agonist for obesity. The trial showed significant weight loss across all doses, with participants on 12 mg retatrutide losing an average of 70.3 lbs (28.3%) over 80 weeks, and up to 85.0 lbs (30.3%) over 104 weeks for those with BMI ≥35. Retatrutide also demonstrated improvements in cardiovascular risk factors and had a safety profile generally consistent with other incretin-based therapies.
Eli Lilly Raises $8.9 Billion in Debt Offering
Eli Lilly & Co completed a multi-billion dollar debt offering, raising approximately $8.94 billion through a mix of floating-rate and fixed-rate notes. The funds are intended to finance the planned acquisition of Centessa and support long-term growth initiatives. Analysts currently rate LLY as an "Outperform" with a $1500 price target, driven by strong financial performance and raised guidance, despite premium valuation concerns.
Eli Lilly Sues COGIC Leaders Over Alleged $200 Million Drug Rebate Scheme
Eli Lilly has filed a civil lawsuit against four leaders of the Church of God in Christ (COGIC), alleging their involvement in a fraudulent drug rebate scheme that defrauded the company of over $200 million. The pharmaceutical giant claims the defendants, including COGIC's secretary-general of health and business and a church bishop along with his children, resold discounted diabetes drugs and collected fraudulent rebates by falsely claiming the medication was distributed to church members. COGIC has stated it has no knowledge of the alleged acts and is investigating the matter, pledging full cooperation with Eli Lilly and authorities.
Lilly’s triple-acting obesity drug hits goal in Phase 3 trial
Eli Lilly's experimental obesity drug, retatrutide, showed significant weight loss in a Phase 3 trial, with some participants losing up to 28% of their body weight over 80 weeks. This triple-acting drug, dubbed a "triple-G," is expected to surpass Lilly's current market leader, Zepbound, and set a new benchmark for competitors like Novo Nordisk. The trial results, which included participants with non-diabetic complications, highlight retatrutide's strong efficacy and acceptable safety profile, potentially expanding Lilly's already substantial obesity franchise.
Leukemia drug revumenib data to headline 4 ASCO 2026 talks
Syndax Pharmaceuticals announced that four abstracts related to its leukemia drug, Revuforj (revumenib), have been accepted for presentation at the ASCO 2026 Annual Meeting. These include an oral presentation on post-transplant maintenance data for acute leukemia patients, as well as posters detailing revumenib's pharmacokinetics and the design of two Phase 3 trials for newly diagnosed NPM1m or KMT2Ar AML. The presentations will highlight favorable outcomes and important profiles of the drug, while also reiterating warnings about potential adverse reactions like differentiation syndrome and QTc prolongation.
[PREC14A] Seer, Inc. Preliminary Contested Proxy Statement
This preliminary contested proxy statement from the Radoff-JEC Group outlines their intent to nominate three highly qualified directors to Seer, Inc.'s Board at the 2026 Annual Meeting. The group, holding approximately 7.8% of outstanding Common Stock, argues that significant board changes are necessary due to Seer's poor financial performance, consistent stock undervaluation compared to its net cash, and questionable corporate governance practices. They advocate for a strategic review and a potential sale of the company to maximize stockholder value.
EU advisers back Allergan’s Boey, a wrinkle shot that works in 8 hours
Allergan Aesthetics, an AbbVie company, received a positive opinion from the CHMP for its product Boey (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults. The recommendation covers 30 EU/EEA markets and is supported by two Phase 3 trials showing rapid onset of effect within 8 hours and efficacy lasting 2-3 weeks, with a safety profile similar to placebo. This moves the company closer to potential European Commission approval and commercial launch, expanding its aesthetics portfolio in Europe.
Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs
This article highlights three resilient healthcare ETFs for investors seeking stability and long-term growth in the healthcare sector. It emphasizes healthcare's recession-resistant nature due to constant demand for medical care and prescription drugs, and discusses how innovation continues to drive expansion. The ETFs covered are Vanguard Health Care ETF (VHT) for broad exposure, iShares U.S. Medical Devices ETF (IHI) for targeted medical device innovation, and Global X HealthTech ETF (HEAL) for digital healthcare transformation.
Pfizer Inc. Trade Ideas — BX:PFEUSD
This article compiles various trade ideas and analyses for Pfizer (PFE) stock, highlighting both bullish and bearish perspectives. A significant focus is on Pfizer's potential in the GLP-1 market with its oral weight-loss drugs, danuglipron and lotiglipron, which some analysts believe could be a game-changer despite the company's recent stock decline and patent expiry challenges. Other analyses discuss technical indicators, support/resistance levels, and fundamental concerns such as patent cliffs and declining COVID-19 related sales, ultimately presenting a mixed outlook for investors.
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County
The Shapiro Administration is calling for increased funding to expand Pennsylvania's innovation economy, with Governor Josh Shapiro proposing nearly $100 million for the Innovate in PA 2.0 program in his 2026-27 state budget. This initiative aims to support key industries like life sciences, robotics, technology, energy, manufacturing, and agriculture, building on the state's historical leadership in discovery and innovation. During a visit to Thermo Fisher Scientific, DCED Secretary Rick Siger emphasized the importance of strategic investments to foster this vital ecosystem and attract industry leaders.
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
The first quarter of this year saw an uptick in biopharma sales, with eight of the top-25 companies achieving double-digit year-over-year growth, compared to six in each quarter of 2025. Eli Lilly led the growth with a 56% increase, extending its reign as the top performer for six consecutive quarters. Other significant contributors to this growth included Regeneron, AstraZeneca, AbbVie, Sandoz, Johnson & Johnson, Astellas, and Daiichi Sankyo, while Novo Nordisk experienced the largest sales decline for the second consecutive quarter.
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Eli Lilly has announced promising results for its experimental injectable drug, retatrutide, which targets three weight-related hormones. The drug helped overweight or obese individuals lose up to 28% of their body weight over 1.5 years, a reduction comparable to bariatric surgery. While offering significant weight loss, the drug shares similar GI side effects with other medications in its class, and further studies are ongoing to compare its efficacy and additional health benefits against existing treatments like tirzepatide.
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer - Global Forecast to 2030 and 2035
The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market is projected to grow from $15.5 billion in 2025 to $18.02 billion in 2026, reaching $32.87 billion by 2030, driven by rising obesity rates, new drug approvals like Eli Lilly's Zepbound, and increased insurance coverage. Key players include Novo Nordisk A/S, Eli Lilly and Company, and Pfizer Inc. While tariffs pose cost challenges, they also encourage domestic production, contributing to the market's robust growth trajectory and innovation in therapies beyond diabetes management.
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Lower-cost oral weight-loss medications from Novo Nordisk (Wegovy) and Eli Lilly (Foundayo) are leading patients to switch from less regulated compounded drugs to the branded options, according to doctors. While insurance coverage remains a significant hurdle, the new pills are expanding the market for GLP-1 treatments, with Novo benefiting from brand recognition and heart data, and Foundayo offering convenience. Doctors anticipate increased government and commercial coverage will further drive demand for these FDA-approved drugs.
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert
AstraZeneca PLC (US6549022043) remains a focus for investors in May 2026 due to updated analyst commentary and new pipeline developments, particularly in its respiratory portfolio. Analysts see a moderate upside potential for the stock, with an average 12-month price target of USD 205.33, implying differing views on the company's future growth trajectory. The company’s pipeline success, especially in biologics for respiratory conditions, along with its strong presence in oncology and cardiovascular treatments, are key drivers for its valuation and long-term earnings profile.
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Eli Lilly's experimental obesity drug, retatrutide, helped patients lose over 28% of their body weight in an 80-week trial, with some losing 30% or more, rivaling bariatric surgery. The company aims for regulatory approval and a potential launch next year, positioning retatrutide as a powerful contender in the obesity treatment market. Concerns about side effects like dysesthesia were eased by improved safety data in the latest trial.
Eli Lilly Experimental Drug Shows Surgery-Level Weight Loss in Phase 3 Trial
Eli Lilly's experimental drug, retatrutide, has demonstrated unprecedented weight loss in Phase 3 clinical trials, achieving an average reduction of 28% over 18 months, which is comparable to bariatric surgery outcomes. This "triple agonist" targets three hormone receptors (GLP-1, GIP, and glucagon), distinguishing it from current GLP-1 therapies. While the drug shows significant promise in treating obesity and related comorbidities, regulatory approval will depend on a thorough review of its safety profile and long-term data.
Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case
Eli Lilly's stock performance is analyzed, with the company reporting strong Q1 2026 revenues driven by Mounjaro and Zepbound. While Wall Street projects an 18% upside, a bull case target of $1,800 by 2030 is presented, contingent on global scaling of new drugs, maintaining performance margins, and timely manufacturing capacity expansion. The article highlights both current market pressures, such as pricing issues and competition from Novo Nordisk, and potential growth drivers like accelerating EPS and new product launches.
Eli Lilly continues with several acquisitions: Buys company in new deal
Eli Lilly has acquired Engage Biologics, a US biotech company specializing in non-viral gene delivery systems, for up to USD 202 million. This acquisition adds to Eli Lilly's series of recent strategic investments, including Ajax Therapeutics, Centessa Pharmaceuticals, Ventyx Biosciences, and Orna Therapeutics, as the pharmaceutical giant continues to expand its pipeline through company buyouts. The deal grants Eli Lilly access to Engage Biologics' Tethosome platform, designed to improve DNA delivery.
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
Eli Lilly's experimental weight loss drug, retatrutide, led to an average weight loss of up to 28% (about 70 pounds) and up to 85 pounds in some patients during a late-stage clinical trial. This effectiveness is comparable to bariatric surgery, making it potentially a "game changer" for those with severe obesity or who don't respond to current GLP-1 drugs. While promising, common side effects like nausea and constipation were reported, and the drug has not yet been submitted for FDA approval.
Eli Lilly & Co (NYSE:LLY) Proves a Smart Pick for a Rules-Based Dividend Growth Strategy
Eli Lilly & Company (LLY) is highlighted as an attractive candidate for a rules-based dividend growth strategy, despite a modest current yield of 0.69%. The company boasts strong financial health, exceptional profitability, and a dividend growth rate of 15.17% over the past five years, supported by explosive growth in EPS and revenue. While its P/E ratio appears high, it is justified by its industry position and future growth prospects.
SNPG | Xtrackers S&P 500 Growth ESG ETF
This article provides a detailed overview of the Xtrackers S&P 500 Growth ESG ETF (SNPG), including its current trading price, key statistics, holdings, and company profile. It highlights the ETF's focus on large-cap growth stocks from socially conscious companies with environmental responsibility, excluding sectors like tobacco and controversial weapons. The article also includes performance metrics, dividend information, and technical analysis indicators for SNPG.
Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs
This article highlights three resilient healthcare ETFs for investors seeking stability and long-term growth. The Vanguard Health Care ETF (VHT) offers broad exposure to the healthcare sector with a low expense ratio. The iShares U.S. Medical Devices ETF (IHI) focuses on medical innovation, while the Global X HealthTech ETF (HEAL) capitalizes on the digital transformation in healthcare.
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer (PFE)?
Pfizer recently announced strong Phase 2 data for its 25-valent pneumococcal vaccine in infants and secured European approval for HYMPAVZI's expanded use in hemophilia patients. These developments enhance Pfizer's position in complex vaccines and rare hematology, aligning with its strategy to offset patent expirations and pricing pressures through targeted innovation. Investors are encouraged to consider these pipeline successes against ongoing challenges like patent Cliffs and drug price reforms affecting future earnings and dividend stability.
ProShare Advisors LLC Purchases 19,018 Shares of CVS Health Corporation $CVS
ProShare Advisors LLC increased its stake in CVS Health Corporation by 7.7% in the fourth quarter, acquiring an additional 19,018 shares, bringing its total holdings to 264,715 shares valued at $21.0 million. This comes as CVS Health reported strong quarterly results, exceeding revenue and earnings estimates, and raised its FY 2026 EPS guidance. Analysts generally maintain a positive outlook on the company, although insider Tilak Mandadi sold a significant number of shares.
Callahan Advisors LLC Acquires Shares of 12,641 Xylem Inc. $XYL
Callahan Advisors LLC has initiated a new position in Xylem Inc. (NYSE:XYL), purchasing 12,641 shares valued at approximately $1.72 million in the fourth quarter. This move comes as Xylem reported strong Q1 earnings, beating analyst expectations with $1.12 per share on $2.13 billion in revenue, and subsequently raised its full-year 2026 EPS guidance. The company also announced a $1.5 billion share buyback program and a quarterly dividend of $0.43 per share, reinforcing a "Moderate Buy" consensus rating from analysts with an average price target of $152.77.
Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline
Inmune Bio Inc (INMB) is preparing to release its full-year 2025 financial results and provide a corporate update on March 30, 2026. The clinical-stage biotechnology company focuses on developing therapies for neuroinflammatory and oncological diseases, with a significant pipeline in Alzheimer's disease. Investors are closely watching for updates on cash runway, strategic priorities, and clinical milestones, given the company's reliance on capital markets and the early stage of its drug development.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" rating from thirteen brokerages, with a consensus one-year price target of $79.18. Analyst actions have been mixed, including an upgrade by Wedbush and price target adjustments by other firms, while Wall Street Zen downgraded the stock to "hold." The company recently reported a wider-than-expected quarterly loss but exceeded revenue estimates.
Chandan S. Joins Eli Lilly and Company as Senior Director – Data Science and AI Engineering
Chandan S. has been appointed as Senior Director – Data Science and AI Engineering at Eli Lilly and Company, enhancing the firm's capabilities in AI, machine learning, and advanced analytics for the life sciences sector. He brings extensive experience from previous senior leadership roles at Axtria – Ingenious Insights and WNS Global Services, focusing on AI-driven analytics, Generative AI, and digital transformation. This strategic hire underscores Eli Lilly and Company's commitment to leveraging advanced technologies for research, commercialization, and patient engagement.
Experimental Drug Yields Dramatic Weight Loss
Eli Lilly announced that its experimental drug, retatrutide, led to dramatic weight loss in trial participants, with some losing 28 percent of their body weight in 80 weeks. These results are comparable to gastric bypass surgery for the heaviest patients and position retatrutide as potentially the most powerful obesity drug yet. However, the drug does cause significant gastrointestinal side effects at higher doses.
Inside Incyte’s $120 Million AI For Drug Development Deal
Incyte has signed a $120 million deal with Genesis Molecular AI for drug development, involving $80 million upfront and a $40 million equity investment, with potential for over $1 billion in milestone payments and royalties. This partnership integrates Incyte's proprietary data with Genesis's AI model to accelerate drug discovery across various therapeutic areas. Meanwhile, Apnimed has filed for regulatory approval for a sleep apnea drug, and Isomorphic Labs continues to raise significant capital for its AI-driven drug development efforts, focusing on an internal pipeline.
iShares U.S. Pharmaceuticals ETF outperforms despite drug pricing policy risks, up 38% in 12 months.
The iShares U.S. Pharmaceuticals ETF (IHE) has significantly outperformed over the past year, gaining 38% despite potential negative impacts from U.S. drug pricing policies. This success is attributed to strong dividend yields and robust drug pipelines from major holdings like Eli Lilly and Johnson & Johnson, particularly due to GLP-1 drug advancements. While attractive for investors near retirement, the ETF has concentration risk and faces policy uncertainties.
Anthropic signs enterprise AI deal with Bristol Myers Squibb
Bristol Myers Squibb has signed a strategic agreement with Anthropic to deploy its Claude AI across various functions including research, manufacturing, and commercial operations. This deployment aims to enhance drug discovery, automate clinical development processes, and integrate AI into all scientific and commercial aspects with robust governance. The collaboration reflects a broader trend of biopharma companies partnering with AI firms to leverage technology for innovation and operational efficiency.
HCW Biologics Jumps, Doubles Again as Traders Pile Into Biotech Name
HCW Biologics Inc. shares surged over 100% due to new securities filings, an ongoing Nasdaq listing dispute, and strong first-quarter results. The company is seeking to raise up to $5.6 million through stock or warrants to fund preclinical and clinical work, while also addressing a Nasdaq minimum bid price issue. Despite the rally, HCW faces risks including cumulative net losses and the need to secure financing and positive human data for its drug candidates.
Bristol Myers deepens AI investment with Anthropic deal
Bristol Myers Squibb is expanding its use of artificial intelligence by partnering with Anthropic to deploy its Claude AI tool across its operations. The drugmaker intends for Claude to accelerate software and AI development, aid in research, development, and manufacturing, and tap into the company's institutional knowledge. This move follows similar AI investments by other major pharmaceutical companies like Merck, Novo Nordisk, Takeda, and Lilly, highlighting a growing industry trend to leverage AI for more efficient drug discovery and development, despite challenges like data quality and AI "hallucinations."
Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme
Eli Lilly has filed a civil lawsuit alleging a $200 million rebate fraud scheme involving its diabetes drug, Trulicity. The lawsuit accuses several bishops and leaders of the Church of God in Christ, along with a mail-order pharmacy called DrugPlace and an organization called Community Health Initiative, of participating in the fraud. Lilly claims these entities used church members to support false rebate claims and resold the drug on the secondary market while collecting fraudulent rebates.
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
Bristol Myers Squibb is partnering with Anthropic to integrate its Claude AI model across its operations, aiming to accelerate drug discovery, development, manufacturing, and medical affairs for over 30,000 employees. The company's stock (BMY) saw a 1.74% rise following the announcement, reflecting investor interest in AI's potential to enhance efficiency in the pharmaceutical sector. Analysts maintain a Moderate Buy rating on BMY, with an average price target suggesting an 8.36% upside.
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans
Ionis Pharmaceuticals saw its stock rise after Biogen announced plans for registrational studies for diranersen, following positive Phase 2 CELIA data in early Alzheimer's disease. The antisense therapy, which targets tau, showed robust biomarker and cognitive improvements, positioning Ionis for potential late-stage development in a large disease area. Despite a primary endpoint miss on dose response, the overall data package was deemed strong enough to pursue further investment.
Mangoceuticals (NASDAQ: MGRX) Q1 2026 shows small sales, heavy loss and thin cash
Mangoceuticals Inc. reported a Q1 2026 net loss of $3.4 million on revenues of $67,864, down from the prior year, with significant spending on operations and stock-based compensation. The company's cash and cash equivalents dwindled to $174,562, highlighting severe liquidity concerns and the need for new financing. Intangible assets, primarily patents and licenses, comprise the majority of the company's total assets, while liabilities remain relatively modest.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $6.89 Million in Republic Services, Inc. $RSG
Fideuram Intesa Sanpaolo Private Banking S.P.A. recently invested $6.89 million in Republic Services, Inc. by purchasing 32,529 shares. This investment aligns with other institutional activities, like Cascade Investment's significant share purchases, following Republic Services' strong first-quarter earnings beat and a declared quarterly dividend. Analysts currently maintain a "Hold" consensus with an average price target of $245.15.
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times
A BioSpace analysis of CEO-to-median-employee pay ratios across 10 major pharmaceutical companies found Johnson & Johnson's Joaquin Duato had one of the highest ratios at 358 to 1, earning $32.6 million while his median employee made $91,000. In contrast, Vertex Pharmaceuticals CEO Reshma Kewalramani had the lowest ratio at 80 to 1, due to a median employee salary of $264,487. Eli Lilly's David Ricks and Pfizer's Albert Bourla also had high ratios, while overall CEO pay continued to rise across industries in 2025.
Eli Lilly & Co. stock (US5324571083): Recent catalyst to watch
Eli Lilly shares are commanding significant investor attention due to the company's central role in the surging obesity and diabetes drug market. Its business model, heavily reliant on chronic disease treatments with long-term use, makes the stock sensitive to prescription trends and new product launches. The company's performance and pipeline developments are closely watched as indicators for broader healthcare and specialty pharma trends.
